Refractory Heart Failure in Noncompaction Cardiomyopathy Despite Guideline-Directed Therapy: A Case Series. [PDF]
Tumkur Panduranga V +5 more
europepmc +1 more source
ABSTRACT We evaluated the renal outcomes and safety of spironolactone added to renin–angiotensin system inhibitors (RASis) among patients with type 2 diabetes (T2D), given its uncertain role alongside RASis, the cornerstone of T2D with renal disease management.
Wei‐Ren Lin +7 more
wiley +1 more source
Prevalence of Tricuspid Regurgitation and Mortality Outcomes in Patients With Heart Failure: Stratification by Phenotype. [PDF]
Mattig I +9 more
europepmc +1 more source
This Consensus Statement outlines management for nursing care‐dependent older adults (Categories 3–4). Key principles include prioritizing QOL over strict BP targets, avoiding reduction of SBP < 120 mmHg, and implementing stepwise deprescribing. It also emphasizes safety protocols during bathing and rehabilitation to prevent adverse event.
Yoshio Iwashima +7 more
wiley +1 more source
Clinical research progress of renal denervation for heart failure treatment: current evidence, controversies, and future directions. [PDF]
Zhang D, Wang D, Wang X, Yu J, Liu B.
europepmc +1 more source
Pulmonary Hypertension in HFpEF and HFrEF
Marco Guazzi, Stefano Ghio, Yochai Adir
openaire +1 more source
Abstract Background Previous studies have identified distinct subgroups (phenogroups) of patients with heart failure with preserved ejection fraction (HFpEF). Aims This study aims to identify distinct phenotypes in older patients with HFpEF hospitalised for acute heart failure (AHF) and investigate the relationship between subgroups and outcomes ...
Maria Livia Burzo * +10 more
wiley +1 more source
EuroSCORE II: Current limitations and physiological gaps in risk stratification
Abstract Risk stratification remains critical in cardiac surgery, enabling clinicians to predict adverse outcomes and guide perioperative management. The European System for Cardiac Operative Risk Evaluation (EuroSCORE) II, introduced in 2011, incorporates 18 key variables to provide an evidence‐based approach to risk assessment.
Jing Yong Ng +7 more
wiley +1 more source
Durable Remission After Triple Therapy in New-Onset HFrEF: Implications for a Strategy of "Personalized GDMT". [PDF]
Pitonak M +3 more
europepmc +1 more source
Leveraging the Translational Science Benefits Model to plan and measure early impact in the heart failure polypill implementation trial in Sri Lanka. [PDF]
Hively A +9 more
europepmc +1 more source

